

The Purdue Frederick Company

One Stamford Forum Stamford, CT 06901-3431 **1 4 6 9 '03 MAR 2b**3) **3b3526** Fax (203) 588 8850 www.purduepharma.com

> Via Federal Express SUBMITTED IN TRIPLICATE

Dockets Management Branch (HFA-305) Food and Drug Administration Room 1061 5630 Fishers Lane Rockville, MD 20852

RE: Docket No. 78N-036L Comments No. RPT13 and ANS6

Dear Sir/Madam:

March 28, 2003

Reference is made to our submissions to the subject Docket dated June 30, 1999, March 27, 2001 and April 16, 2001 in support of the safety of senna as a Category I OTC laxative drug ingredient and your letters of February 29, 2000 and March 27, 2001.

This study was conducted in response to the Food and Drug Administration's request (FR 33592) for further testing to support Category I status of senna-containing OTC laxative drug products. The purpose of this study (Purdue Pharma LP; study no. DSE-312-GLP) was to investigate the potential carcinogenic response to Senna after oral administration to Sprague-Dawley rats (60/sex/group in the main study and 18/sex/group in the toxicokinetic groups) at dose levels of 0, 0, 25, 100 and 300 mg/kg/day for up to 104 consecutive weeks. The study was conducted at ClinTrials BioResearch(CTBR) (Montreal, Canada). Four companies sponsored the study: Purdue Pharma LP (Stamford, CT), Madaus AG (Koln, Germany), Novartis Consumer Health (Parsippany, NJ) and Reckitt and Benckiser (Hull, UK).

The results of this study show that lifetime daily administration of Senna-MIS to Sprague-Dawley rats, at dosage levels of up to 300 mg/kg/day, did not reveal any evidence that Senna-MIS is a carcinogen.

Therefore, based upon the data presented in this submission, The Purdue Frederick Company respectfully requests that senna-containing laxatives be reclassified from Category III to Category I in the Final Monograph for OTC Laxative Drug Products.

78N-036L

RPTID



March 28, 2003 Page 2

Please do not hesitate to contact me for further information at (203) 588-8107.

Sincerely, For The Purdue Frederick Company By:


David Darb

David W. Grob, MS, RAC Director Regulatory Affairs OTC & Labeling Purdue Pharma L.P. Phone: (203) 588-8107 Fax: (203) 588-6229

.

Enclosure

Purdue Study Number. DSE-312-GLP Madaus AG Study Number: TX220





A Member of the Inveresk Research Group

88633

STUDY TITLE:

AN ORAL CARCINOGENICITY STUDY OF SENNA-MIS IN THE ALBINO RAT

TESTING FACILITY:

ClinTrials BioResearch Ltd 87 Senneville Road Senneville Quebec, Canada H9X 3R3

TESTING FACILITY PROTOCOL NUMBER:

PPLP, MADAUS PROJECT NUMBER:

TESTING FACILITY STUDY DIRECTOR:

DSE-312-GLP, TX220

Susan M McPherson, MSc Senior Research Scientist Phone: 514 630 8200; X 8703 Fax: 514 630 8230

Email: toxicology@ctbr.com

SPONSORS:

Purdue Pharma L.P. 444 Saw Mill River Road, Ardsley, NY 10502

Madaus AG, Ostmerheimer Strasse 198 D-51109 Köln, Germany

Novartis Consumer Health 200 Kimball Drive, Parsippany NJ, 07054-0622

Reckitt & Benckiser Dansom Lane Hull, HU8 7DS

VOLUME: PAGES: 1 of 11

1 of 3547

Purdue Study Number. DSE-312-GLP Madaus AG Study Number: TX220

APPROVAL OF STUDY REPORT

Reviewed By:

P. Batham **Scientific Director** General Toxicology

4 Manl 2003 Date

CTBR No. 88633